Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPH5008-A is a small molecule therapeutic candidate being developed by Shanghai Pharmaceuticals for the treatment of arthritis-related diseases. It is a sustained-release formulation of lornoxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Lornoxicam functions as a potent inhibitor of the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are responsible for the production of prostaglandins that mediate pain and inflammation. By utilizing a sustained-release delivery system, SPH5008-A aims to maintain therapeutic plasma concentrations over a longer period, potentially reducing dosing frequency and improving patient compliance compared to immediate-release lornoxicam. The drug is currently in Phase 2 clinical trials for indications such as osteoarthritis and rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SPH5008-A.